"Inside alive bound limits, the most important award inside the domain that nobel prize is considered as place to award prize normally, the person that promulgates to make the most significant contribution to the mankind... "
Duration motherland 69 weeks of time birth during, beijing time on October 1 17 when 30 minutes, global millions of people fixes eyes upon Nobel is physiological 2018 or medical award result is announced, zhanmusi Ailisen of American immunology home (James P Allison) with Ben Shuyou of Japanese immunology home (Tasuku Honjo) because be in,tumor immunity domain highlights contribution for what the mankind makes and obtain this special honour.
American heart the outstanding contribution of Professor Zhanmusi Ailisen of center of university Anderson cancer depends on Kesasi discover CTLA-4 " molecular brake " action, restrain this element to will make T cell a large number of hyperplasia, then atttacks tumor cell. Ben Shuyou of Japanese immunology home is the detector that at present tumor immunity treats PD-1 of domain star element, its contribution is labelled first what 10 big science break through scientific 2013 journal.
But regretful is, the outstanding primary contribution that achieve a gender is made in domain of tumor immunity cure, most the scientist of foreign citizen of Chinese origin that devotes oneself to PD-1 cancer treatment first displays smooth professor to be omited.
You want to be accomplished somewhat in a domain, do not want too consideration others is evaluated to yours. As a researcher, often do not want to enter mainstream science, because once become ' mainstream scientist ' , the innovation ability that shows you then can have a problem-- display smooth professor
The field is treated in the tumor immunity that is a delegate with PD-1, display smooth professor to serve as the detector of PD-L1, those who started tumor therapy is brand-new concept, it is the precursor that immunity of tumour of contemporary whole world treats.
Came 1999 2002, displayed smooth professor to discover have the PD-1/PD-L1 access that controls function of tumor immunity reaction, and was built alone be target with PD-1/PD-L1 access to cancer immunity therapeutics, PD-1/PD-L1 antibody also is known as accordingly " tumor treats antibiotic " .
2006, display smooth professor to initiate and assistance organized the cancer that the whole world snaps PD-1/PD-L1 route first times with antibody block to treat clinical trial, at the same time development goes to label as biology with PD-L1 coloring content detects the diagnostic method of cancer, its study achievement has epoch-making sense to cancer treatment.
The achievement benefit that displays smooth professor the tumor patient of two hundred and seventy-six million four hundred and forty-seven thousand two hundred and thirty-two, for them bleak life and its family sent new detailed sunshine, the far award that compare Nuo is more important.
Come nearly 10 years, tumor immunity is treated in the ascendant. It is with liver cell cancer exemple, in global cancer overall mortality with annual below the circumstance with the rate degressive year after year of 1.5 ％ , the rate of die in one's bed of cancer of the liver appears to rise continuously however trend, be opposite especially China, its are overall disease burden is heavier still. Do not be able to bear or endure to alling alone Lafeini is reached via treating the patient of liver cell cancer that get, its medication progress times get attention.
September 2017, management board of American food medicines and chemical reagents agrees to accelerate approval Nivolumab (fight PD-1 antibody) use at treating Suolafeini via treated liver cell cancer. Study the result shows, in the patient of more than 90 ％ , apply Nivolumab 6 the month is longer even, always businesslike be close to 15 ％ . Block of immune check check the number of broke the cure of liver cancer of the cell that it is liver to offer new alternative. In the meantime, to heighten curative effect further, block of immune check check the number of breaks a likelihood to still need to combine other treatment, the tumor cell cycle that puts forward like the near future depends on albumen kinase (Activation Of Cell Cycle-related Kinase, CCRK) depressor.
If I am only dedicated basic research, so I may publish times more than now article, because I have the energy of 50% ,expenditure is changing medicine to go up. Do research, do clinical, do a business, need understanding differs 3 kinds ' language ' , it is not easy to accomplish this--Display smooth professor
If not be this second with nobel prize just miss the opportunity, the displays smooth professor and him to develop place to make for human medicine outstanding contribution that perhaps the masses won't observe low-key deal with concrete matters relating to work.
Lose an election reason already somebody is discussed, no matter be home values insufficient, conduct propaganda to relevant test positive result,build situation is adverse, still be Chinese scientist suffers cold shoulder in western society, also or it is problem of existence of Nobel selection mechanism, be worth us to think over.
We " special " neighbour -- Japan, 18 years, 18 people, "50 years of 30 Nuo award " the target already had come true half, in literary science the domain outputs energy continuously to the world. Perhaps, the target the reverse side that appears utility sees in that, it is a lot of and worth while to still have we learn the place that draw lessons from.
"The Chinese is not good at taletelling, do not be good at turning into complex science simple idea goes letting people accept, this may be our biggest drawback "-- display smooth professor near future to accept the say when interviewing
Contribute / tall edge boat
Editor / Xing Xiangyu
